Hematology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "Gilteritinib"

The results from the phase 3 ADMIRAL clinical trial comparing Gilteritinib ( Xospata ) to salvage chemotherapy in adult patients with relapsed or refractory acute myeloid leukemia ( AML ) with a FLT3 ...

Patients assigned to Gilteritinib ( Xospata ) were found to have a 36% reduction in risk of death compared with those assigned to standard chemotherapy. Median overall survival was 9.3 months for tho ...

Acute myeloid leukemia ( AML ) remains a highly resistant disease to conventional chemotherapy, with a median survival of only 4 months for relapsed and/or refractory disease. Molecular profiling b ...